CompletedPhase 3NCT01047839
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
Studying Encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Valneva Austria GmbH
- Principal Investigator
- Andrea Ayad, Dr.Valneva Austria GmbH
- Intervention
- IC51(biological)
- Enrollment
- 100 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2010 – 2013
Study locations (10)
- Tampa Clinical Research Inc., Tampa, Florida, United States
- Passport Health, Baltimore, Maryland, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Bronx Lebanon Hospital Center, New York, New York, United States
- Dr. Deb - The Travel Doctor, Brisbane, Queensland, Australia
- Travel Doctor - TMVC Australia, Melbourne, Victoria, Australia
- Danske Laegers Forsknings Center, Søborg, Denmark
- Berliner Zentrum für Reise- und Tropenmedizin, Berlin, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- City Akuten Wasa Vaccination, Stockholm, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01047839 on ClinicalTrials.govOther trials for Encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07511049Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot StudyNational Institute of Neurological Disorders and Stroke (NINDS)
- ACTIVE NOT RECRUITINGNCT07554261Clinical Features and Outcomes of VZV CNS InfectionsKocaeli University
- RECRUITINGNCT07332234Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesSpitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
- ACTIVE NOT RECRUITINGNCT06820060Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel PlusQIAGEN Gaithersburg, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineBavarian Nordic
- RECRUITINGPHASE1, PHASE2NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsSK Bioscience Co., Ltd.
- RECRUITINGNCT06368648CoMind Early Feasibility StudyCoMind Technologies Limited
- ACTIVE NOT RECRUITINGPHASE4NCT06678373Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasLiaoning Chengda Biotechnology CO., LTD